We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Intra-Cellular Therapies (ITCI) Could Be Positioned for a Surge
Read MoreHide Full Article
Intra-Cellular Therapies, Inc. (ITCI - Free Report) is a biopharmaceutical that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ITCI’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Intra-Cellular Therapies could be a solid choice for investors.
Current Quarter Estimates for ITCI
In the past 30 days, 1 estimate has gone higher for Intra-Cellular Therapies while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates with estimates narrowing from a loss of 93 cents a share 30 days ago, to a loss of 77 cents today, a move of 17.2%.
Current Year Estimates for ITCI
Meanwhile, Intra-Cellular Therapies’s current year figures are also looking quite promising, with 3 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $3.14 per share 30 days ago to a loss of $2.82 per share today, an increase of 10.2%.
The stock has also started to move higher lately, adding 14.4% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Intra-Cellular Therapies (ITCI) Could Be Positioned for a Surge
Intra-Cellular Therapies, Inc. (ITCI - Free Report) is a biopharmaceutical that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ITCI’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Intra-Cellular Therapies could be a solid choice for investors.
Current Quarter Estimates for ITCI
In the past 30 days, 1 estimate has gone higher for Intra-Cellular Therapies while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates with estimates narrowing from a loss of 93 cents a share 30 days ago, to a loss of 77 cents today, a move of 17.2%.
Current Year Estimates for ITCI
Meanwhile, Intra-Cellular Therapies’s current year figures are also looking quite promising, with 3 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $3.14 per share 30 days ago to a loss of $2.82 per share today, an increase of 10.2%.
INTRA-CELLULAR Price and Consensus
INTRA-CELLULAR Price and Consensus | INTRA-CELLULAR Quote
Bottom Line
The stock has also started to move higher lately, adding 14.4% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>